GLS and melanoma: We demonstrated that inhibition of GLS1 by CB-839 eliminated 30–50% of palbociclib-induced senescent BrafWTNrasWT and BrafV600E melanoma cells (palbociclib treatment for 8 days) by induction of senolytic cell death, but not palbociclib-induced cell cycle arrested cells (palbociclib treatment for 1 day) (Fig. 2B).